Literature DB >> 2345228

Predicting late restenosis after coronary angioplasty by very early (12 to 24 h) thallium-201 scintigraphy: implications with regard to mechanisms of late coronary restenosis.

R Hardoff1, A Shefer, S Gips, A Merdler, M Y Flugelman, D A Halon, B S Lewis.   

Abstract

To examine whether late coronary restenosis may be predicted by abnormalities of myocardial perfusion in the early hours after successful percutaneous transluminal coronary angioplasty and to study in greater detail the mechanisms involved in the development of late coronary restenosis after angioplasty, a prospective study was undertaken in 90 consecutive patients. Thallium-201 scintigrams were recorded at rest and during the stress of atrial pacing, 12 to 24 h after angioplasty, and the results were related to the findings at angiography in 70 patients undergoing late cardiac catheterization. A reversible thallium-201 perfusion defect was found in 39 (38%) of 104 myocardial regions supplied by the dilated coronary vessel and identified a subset of patients at high risk of late (6 to 12 months) angiographic restenosis (sensitivity 77%, specificity 67%). In contrast, late coronary restenosis developed in only 7 (11%) of 65 vessels and in 5 (14%) of 37 patients with a nonischemic thallium-201 scintigram on day 1 (p less than 0.005). Multivariate logistic regression analysis of 14 possible preangioplasty and periangioplasty clinical and angiographic variables selected reversible perfusion defect on the thallium-201 scintigram on day 1 (p = 0.016) and immediate postangioplasty residual coronary narrowing (p = 0.004) as significant independent predictors of late restenosis, with younger patient age as an additional less powerful predictor (p less than 0.05). The findings have important implications regarding the pathogenesis of late coronary restenosis in patients undergoing successful angioplasty and they imply that in the majority of these patients pathophysiologic events in the early minutes and hours after angioplasty may determine the development of late restenosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345228     DOI: 10.1016/0735-1097(90)92815-j

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Reperfusion injury components and manifestations determined by cardiovascular MR and MDCT imaging.

Authors:  Maythem Saeed; Steve Hetts; Mark Wilson
Journal:  World J Radiol       Date:  2010-01-28

2.  Nuclear cardiology: the interventionalists' perspective.

Authors:  H L Haronian; H S Cabin
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

Review 3.  Clinical assessment following coronary revascularization.

Authors:  K J Beatt; F Fath-Ordoubadi; T Huehns
Journal:  Int J Card Imaging       Date:  1993

4.  Reversible defects on myocardial perfusion imaging early after coronary stent implantation: a predictor of late restenosis.

Authors:  Dae-Weung Kim; Soon-Ah Park; Chang-Guhn Kim; Cheol Lee; Seok Kyu Oh; Jin-Won Jeong
Journal:  Int J Cardiovasc Imaging       Date:  2008-03-13       Impact factor: 2.357

5.  Diagnostic accuracy of quantitative cardiac MRI evaluation compared to stress single-photon-emission computed tomography.

Authors:  Hideki Futamatsu; Chris Klassen; Marco Pilla; Norbert Wilke; Dominick J Angiolillo; Stuart Smalheiser; Alan Siuciak; Nobuaki Suzuki; Theodore A Bass; Marco A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2007-09-11       Impact factor: 2.357

6.  Role of Stress Myocardial Scintigraphy in the Evaluation of Incompletely Revascularized Post-PCI Patients.

Authors:  Alfredo R Galassi; Francesco Marzá; Salvatore Azzarelli; Salvatore D Tomasello
Journal:  Int J Mol Imaging       Date:  2011-09-21

Review 7.  Myocardial perfusion scintigraphy: the evidence.

Authors:  S R Underwood; C Anagnostopoulos; M Cerqueira; P J Ell; E J Flint; M Harbinson; A D Kelion; A Al-Mohammad; E M Prvulovich; L J Shaw; A C Tweddel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.